Allan L. Shaw is a highly regarded biopharma executive and board member with extensive senior global strategic, financial, M&A, operational, capital markets, and governance experience. He is a five-time public company Chief Financial Officer and has served on seven public boards, including chairing four audit committees and three compensation committees. Mr. Shaw has actively participated in the sourcing, development, and commercialization of various drug products in numerous therapeutic areas.
Mr. Shaw is currently involved with a portfolio of healthcare activities. Most recently, he took Syndax Pharmaceuticals public as its Chief Financial Officer and previously served as a Managing Director of Alvarez & Marsal, a global professional services firm, where he led their biopharmaceutical consulting practice. Mr. Shaw's previous experience includes serving as the Chief Financial Officer of Serono S.A., Portage Biotech Inc., NewLead Holdings Ltd., and Viatel, Inc.
He presently serves on the board of directors of CalciMedica Inc., Evecxia, and the Edith & Carl Marks JCH of Bensonhurst, a non-profit organization where he chairs their finance committee. Mr. Shaw has previously served on the board of directors of Blue Water Vaccines, Vivus, Inc., Akari Therapeutics, Plc., Central New York Biotech Accelerator, NewLead Holdings LTD., Navios Maritime Holdings, Inc., and Serono S.A. as an Executive Management Board Member, as well as Viatel Inc.
Mr. Shaw had a monthly column in Life Science Leader magazine entitled “Deeper Dive- A CFO insider’s view of th… Read More